Literature DB >> 23128515

Pharmacometrics: a quantitative tool of pharmacological research.

Qing-shan Zheng, Lu-jin Li.   

Abstract

Mesh：

Year:  2012        PMID： 23128515      PMCID： PMC4011354          DOI： 10.1038/aps.2012.149

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN： 1671-4083            Impact factor:   6.150


× No keyword cloud information.
  15 in total

Review 1.  Can the pharmaceutical industry reduce attrition rates?

Authors:  Ismail Kola; John Landis
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

2.  Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers.

Authors:  Dong-mei Zhang; Kun Wang; Xia Zhao; Yun-fei Li; Qing-shan Zheng; Zi-ning Wang; Yi-min Cui
Journal:  Acta Pharmacol Sin       Date:  2012-06-04       Impact factor: 6.150

Review 3.  Clinical pharmacology considerations in biologics development.

Authors:  Liang Zhao; Tian-hua Ren; Diane D Wang
Journal:  Acta Pharmacol Sin       Date:  2012-09-24       Impact factor: 6.150

4.  Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.

Authors:  Li-jun Li; De-wei Shang; Wen-biao Li; Wei Guo; Xi-pei Wang; Yu-peng Ren; An-ning Li; Pei-xin Fu; Shuang-min Ji; Wei Lu; Chuan-yue Wang
Journal:  Acta Pharmacol Sin       Date:  2012-07-23       Impact factor: 6.150

5.  Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats.

Authors:  Xin-gang Li; Liang Li; Xuan Zhou; Ye Chen; Yu-peng Ren; Tian-yan Zhou; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2012-06-04       Impact factor: 6.150

6.  Pharmacokinetic-pharmacodynamic modeling of diclofenac in normal and Freund's complete adjuvant-induced arthritic rats.

Authors:  Jing Zhang; Pei Li; Hai-fang Guo; Li Liu; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2012-07-30       Impact factor: 6.150

7.  Comparative pharmacokinetics of cefuroxime lysine after single intravenous, intraperitoneal, and intramuscular administration to rats.

Authors:  Long-shan Zhao; Ran Yin; Bin-bin Wei; Qing Li; Zhen-yuan Jiang; Xiao-hui Chen; Kai-shun Bi
Journal:  Acta Pharmacol Sin       Date:  2012-10-15       Impact factor: 6.150

8.  The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulation.

Authors:  Jun-jie Ding; Yun-jian Zhang; Zheng Jiao; Yi Wang
Journal:  Acta Pharmacol Sin       Date:  2012-10-29       Impact factor: 6.150

9.  Dose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers.

Authors:  Yun-fei Li; Kun Wang; Fang Yin; Ying-chun He; Ji-han Huang; Qing-shan Zheng
Journal:  Acta Pharmacol Sin       Date:  2012-08-06       Impact factor: 6.150

10.  A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects.

Authors:  Sheng Feng; Ji Jiang; Pei Hu; Jian-yan Zhang; Tao Liu; Qian Zhao; Bi-lu Li
Journal:  Acta Pharmacol Sin       Date:  2012-10-22       Impact factor: 6.150
View more
  3 in total

1.  Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration.

Authors:  Shao-qing Ni; Wei Zhao; Jue Wang; Su Zeng; Shu-qing Chen; Evelyne Jacqz-Aigrain; Zheng-yan Zhao
Journal:  Acta Pharmacol Sin       Date:  2013-04-29       Impact factor: 6.150

2.  The first study in pediatric: Population pharmacokinetics of sirolimus and its application in Chinese children with immune cytopenia.

Authors:  Xiaoling Cheng; Yiming Zhao; Hao Gu; Libo Zhao; Yannan Zang; Xiaoling Wang; Runhui Wu
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

3.  Initial dosage optimization of ciclosporin in pediatric Chinese patients who underwent bone marrow transplants based on population pharmacokinetics.

Authors:  Xiao Chen; Xin Yu; Dong-Dong Wang; Hong Xu; Zhiping Li
Journal:  Exp Ther Med       Date:  2020-05-08       Impact factor: 2.447
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.